HUP0301346A2 - Szterotonin agonista (5HT2) és antagonista (5HT6) új kombinációja gyógyászati készítményként és eljárás az előállítására - Google Patents
Szterotonin agonista (5HT2) és antagonista (5HT6) új kombinációja gyógyászati készítményként és eljárás az előállításáraInfo
- Publication number
- HUP0301346A2 HUP0301346A2 HU0301346A HUP0301346A HUP0301346A2 HU P0301346 A2 HUP0301346 A2 HU P0301346A2 HU 0301346 A HU0301346 A HU 0301346A HU P0301346 A HUP0301346 A HU P0301346A HU P0301346 A2 HUP0301346 A2 HU P0301346A2
- Authority
- HU
- Hungary
- Prior art keywords
- antagonist
- receptor
- preparation
- pharmaceutical composition
- ht2c
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 239000000952 serotonin receptor agonist Substances 0.000 title 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 abstract 6
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 abstract 6
- 239000000018 receptor agonist Substances 0.000 abstract 4
- 229940044601 receptor agonist Drugs 0.000 abstract 4
- 239000003751 serotonin 6 antagonist Substances 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 108091005435 5-HT6 receptors Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
A találmány gyógyászati készítményre vonatkozik, amely hatásosmennyiségben tartalmazza egy 5-HT2C receptor agonista és egy 5-HT6receptor angatonista kombinációját, adott esetben gyógyászatilagelfogadható hordozóanyaggal együtt. A találmány továbbá 5-HT2creceptor agonista és 5-HT6 receptor antagonista alkalmazásáravonatkozik az 5-HT2c receptorral és az 5-HT6 receptorral kapcsolatosbetegség kezelésére szánt gyógyászati készítmény előállítására. Atalálmány továbbá egy eljárásra vonatkozik gyógyászati készítményelőállítására, ahol egy 5-HT2c receptor agonistát és egy 5-HT6receptor antagonistát kombinált terápiás mennyiségben alaposanelegyítünk egy gyógyászatilag elfogadható hordozóanyaggal. A találmánytovábbá 5-HT2c receptor agonistát és 5-HT6 receptor antagonistátkombinált készítményként tartalmazó termékre vonatkozik egyidejű,külön-külön vagy egymás utáni alkalmazásra egy, az 5-HT2c receptorralés az 5-HT6 receptorral kapcsolatos betegség, különösen elhízásgyógyítására. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0002754A SE0002754D0 (sv) | 2000-07-21 | 2000-07-21 | New pharmaceutical combination formulation and method of treatment with the combination |
PCT/SE2001/001651 WO2002008178A1 (en) | 2000-07-21 | 2001-07-19 | New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0301346A2 true HUP0301346A2 (hu) | 2003-08-28 |
HUP0301346A3 HUP0301346A3 (en) | 2005-05-30 |
Family
ID=20280577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0301346A HUP0301346A3 (en) | 2000-07-21 | 2001-07-19 | New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical composition and process for its preparation |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1301476A1 (hu) |
JP (1) | JP2004504376A (hu) |
KR (1) | KR100845450B1 (hu) |
CN (1) | CN1221254C (hu) |
AU (2) | AU2001282734B2 (hu) |
BR (1) | BR0112661A (hu) |
CA (1) | CA2411192A1 (hu) |
EA (1) | EA006604B1 (hu) |
HK (1) | HK1057536A1 (hu) |
HU (1) | HUP0301346A3 (hu) |
IL (1) | IL154057A0 (hu) |
MX (1) | MXPA03000548A (hu) |
NO (1) | NO20030304L (hu) |
NZ (1) | NZ523216A (hu) |
PL (1) | PL360309A1 (hu) |
SE (1) | SE0002754D0 (hu) |
WO (1) | WO2002008178A1 (hu) |
YU (1) | YU2603A (hu) |
ZA (1) | ZA200210234B (hu) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2298738B1 (en) * | 2000-11-02 | 2012-09-19 | Wyeth LLC | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
US7034029B2 (en) | 2000-11-02 | 2006-04-25 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
CN1321110C (zh) * | 2001-06-15 | 2007-06-13 | 弗·哈夫曼-拉罗切有限公司 | 具有5-ht6受体亲和力的4-哌嗪基吲哚衍生物 |
MXPA03011638A (es) * | 2001-06-15 | 2004-04-02 | Hoffmann La Roche | Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6. |
US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
DK1497266T3 (da) * | 2002-03-27 | 2008-10-06 | Glaxo Group Ltd | Quinolinderivater og deres anvendelse som 5HT6-ligander |
CL2004000826A1 (es) * | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
US8754238B2 (en) | 2003-07-22 | 2014-06-17 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
EP2400300A1 (en) | 2004-08-25 | 2011-12-28 | Takeda Pharmaceutical Company Limited | Method of screening preventives/remedies for stress urinary incontinence |
US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
US20100048713A1 (en) * | 2006-01-06 | 2010-02-25 | Aarhus Universitet | Compounds acting on the serotonin transporter |
EP2727585A1 (en) | 2006-05-16 | 2014-05-07 | Takeda Pharmaceutical Company Limited | In-vivo screening method |
US20070293475A1 (en) * | 2006-06-20 | 2007-12-20 | Alcon Manufacturing Ltd. | Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma |
DE602007012080D1 (de) * | 2007-08-01 | 2011-03-03 | Esteve Labor Dr | Kombination von mindestens zwei 5-HT6-Liganden |
US20100266504A1 (en) | 2007-11-15 | 2010-10-21 | Takahiro Matsumoto | Condensed pyridine derivative and use thereof |
US9084742B2 (en) | 2007-12-12 | 2015-07-21 | Axovant Sciences Ltd. | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline |
US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
UA100192C2 (en) | 2008-11-11 | 2012-11-26 | УАЙТ ЭлЭлСи | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
TWI542592B (zh) | 2009-06-15 | 2016-07-21 | 武田藥品工業股份有限公司 | 吡並氮雜氧雜環庚烯衍生物 |
JPWO2011071136A1 (ja) | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
KR20180022792A (ko) | 2015-06-12 | 2018-03-06 | 엑소반트 사이언시즈 게엠베하 | 렘 수면 행동 장애의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴 우레아 유도체 |
BR112018000728A2 (pt) | 2015-07-15 | 2018-09-04 | Axovant Sciences Gmbh | resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo |
CN107628981B (zh) * | 2017-10-31 | 2019-07-30 | 威海市妇女儿童医院 | 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用 |
EP3733204A4 (en) | 2017-12-27 | 2021-09-15 | Takeda Pharmaceutical Company Limited | THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE |
CN111269165A (zh) * | 2018-12-05 | 2020-06-12 | 中国科学院大连化学物理研究所 | 一种3-芳基磺酰基吲哚衍生物的合成方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
GB9803411D0 (en) * | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
US6100291A (en) * | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
US6251893B1 (en) * | 1998-06-15 | 2001-06-26 | Nps Allelix Corp. | Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity |
GB9819035D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Res Ltd | Chemical compounds VII |
-
2000
- 2000-07-21 SE SE0002754A patent/SE0002754D0/xx unknown
-
2001
- 2001-07-19 HU HU0301346A patent/HUP0301346A3/hu unknown
- 2001-07-19 KR KR1020037000321A patent/KR100845450B1/ko not_active IP Right Cessation
- 2001-07-19 CA CA002411192A patent/CA2411192A1/en not_active Abandoned
- 2001-07-19 WO PCT/SE2001/001651 patent/WO2002008178A1/en active IP Right Grant
- 2001-07-19 AU AU2001282734A patent/AU2001282734B2/en not_active Ceased
- 2001-07-19 BR BR0112661-0A patent/BR0112661A/pt not_active IP Right Cessation
- 2001-07-19 NZ NZ523216A patent/NZ523216A/en not_active IP Right Cessation
- 2001-07-19 YU YU2603A patent/YU2603A/sh unknown
- 2001-07-19 JP JP2002514087A patent/JP2004504376A/ja not_active Withdrawn
- 2001-07-19 IL IL15405701A patent/IL154057A0/xx unknown
- 2001-07-19 MX MXPA03000548A patent/MXPA03000548A/es active IP Right Grant
- 2001-07-19 AU AU8273401A patent/AU8273401A/xx active Pending
- 2001-07-19 EP EP01961472A patent/EP1301476A1/en not_active Withdrawn
- 2001-07-19 EA EA200300183A patent/EA006604B1/ru not_active IP Right Cessation
- 2001-07-19 CN CNB018131549A patent/CN1221254C/zh not_active Expired - Fee Related
- 2001-07-19 PL PL36030901A patent/PL360309A1/xx not_active Application Discontinuation
-
2002
- 2002-12-18 ZA ZA200210234A patent/ZA200210234B/en unknown
-
2003
- 2003-01-20 NO NO20030304A patent/NO20030304L/no not_active Application Discontinuation
-
2004
- 2004-01-15 HK HK04100306A patent/HK1057536A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2002008178A1 (en) | 2002-01-31 |
PL360309A1 (en) | 2004-09-06 |
NZ523216A (en) | 2005-05-27 |
EA006604B1 (ru) | 2006-02-24 |
EA200300183A1 (ru) | 2003-08-28 |
EP1301476A1 (en) | 2003-04-16 |
NO20030304L (no) | 2003-03-12 |
KR100845450B1 (ko) | 2008-07-10 |
ZA200210234B (en) | 2004-03-18 |
AU8273401A (en) | 2002-02-05 |
CA2411192A1 (en) | 2002-01-31 |
HK1057536A1 (en) | 2004-04-08 |
NO20030304D0 (no) | 2003-01-20 |
MXPA03000548A (es) | 2004-04-05 |
JP2004504376A (ja) | 2004-02-12 |
YU2603A (sh) | 2006-05-25 |
IL154057A0 (en) | 2003-07-31 |
CN1443162A (zh) | 2003-09-17 |
CN1221254C (zh) | 2005-10-05 |
BR0112661A (pt) | 2003-06-24 |
HUP0301346A3 (en) | 2005-05-30 |
SE0002754D0 (sv) | 2000-07-21 |
AU2001282734B2 (en) | 2006-10-12 |
KR20030036599A (ko) | 2003-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0301346A2 (hu) | Szterotonin agonista (5HT2) és antagonista (5HT6) új kombinációja gyógyászati készítményként és eljárás az előállítására | |
HUP0400529A2 (hu) | Klórpromazin és pentamidin alkalmazása daganatképződéssel járó rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására | |
HUP0204163A2 (hu) | Opioid agonistát és antagonistát tartalmazó szabályozott leadású készítmény és eljárás az előállítására | |
JP2004504376A5 (hu) | ||
MX9801305A (es) | Composicion de disolucion rapida oral para agonistas de dopamina. | |
HUP0401344A2 (hu) | Gyógyszerkészítmények opioidokkal való visszaélés megakadályozására, és eljárás előállításukra | |
HUP0003386A2 (hu) | CRF antagonisták alkalmazása depresszió, kardiovaszkuláris betegségek kezelésére szolgáló gyógyszerkészítmények előállítására | |
HUP0002316A2 (hu) | Gyorsan olvadó orális adagolási formák | |
HUP0203586A2 (hu) | Szerotonin újrafelvétel inhibitorának, valamint 5-ht2c antagonistának, inverz agonistának vagy részleges agonistának a kombinációja | |
AP1818A (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | |
EE200300033A (et) | Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon | |
HUP0003848A2 (hu) | Budesonid és formoterol új alkalmazása | |
IT1282352B1 (it) | Composizione farmaceutica, in particolare essiccata mediante congelamento, per somministrazione orale di ondansetron e metodo per | |
HUP0401195A2 (hu) | Averziót okozó szert tartalmazó készítmények opioidokkal való visszaélés megakadályozására | |
HUP0303530A2 (hu) | Szubsztituált pirrolokinolinok és piridokinolinok mint szerotonin-agonisták és -antagonisták és ezeket tartalmazó gyógyszerkészítmények | |
TW200633978A (en) | 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists | |
HUP0300698A2 (hu) | N-acetil-p-aminofenol tartalmú készítmény | |
HUP0101404A2 (hu) | Fluoxetin-hidroklorid alkalmazása hőhullámok csökkentésére | |
HUP0101901A2 (hu) | Gyógyászati készítmény nehezen kezelhető depresszió kombinált gyógyászati kezelésére, valamint kombinált kezelési eljárás | |
HUP0102913A2 (hu) | Biogén ösztrogén-szulfamátok alkalmazása hormonhelyettesítő terápiánál használható gyógyszerkészítmények előállítására | |
HUP0003953A1 (hu) | Készítmények cerebrális neurovaszkuláris zavarok és muszkuláris eredetű fejfájások gátlására | |
RU2218917C2 (ru) | Применение специфического антагониста 5ht2 рецепторов для приготовления лекарств, пригодных для лечения синдрома апноэ во сне | |
HUP0002346A1 (hu) | Emlősök elmezavarainak kezelésére szolgáló gyógyszerkészítmény | |
HUP0401042A2 (hu) | Primer álmatlanság kezelésére alkalmas gyógyszerkészítmények | |
HUP9902135A2 (hu) | (+)-alfa-(2,3-Dimetoxi-fenil)-1-[2-(4-fluor-fenil)-etil]-4-piperidin-metanol alkalmazása depresszív és bipoláris rendellenességek kezelésére alkalmas gyógyszerkészítmény előállítására |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB9A | Succession in title |
Owner name: BIOVITRUM AB (PUBL), SE Free format text: FORMER OWNER(S): BIOVITRUM AB., SE |
|
FD9A | Lapse of provisional protection due to non-payment of fees |